This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Donnelly, R. Articles by Reid, J. L. Search for Related Content PubMed PubMed Citation Articles by Donnelly, R. Articles by Reid, J. L.

Hypertension, Vol 15, 301-309, Copyright © 1990 by American Heart Association

ARTICLES

Kinetic-dynamic relations and individual responses to enalapril

R Donnelly, PA Meredith, HL Elliott and JL Reid
University Department of Medicine and Therapeutics, Stobhill General Hospital, Glasgow, United Kingdom.

Pharmacokinetic and pharmacodynamic variability largely account for interindividual differences in the response to antihypertensive drugs including angiotensin converting enzyme inhibitors. The factors determining the response to enalapril have been investigated in a placebo-controlled study in essential hypertension. The effects of placebo, the initial dose of enalapril, and long-term (1 and 6 weeks) treatment with enalapril were studied in 13 subjects. By using an integrated kinetic-dynamic model that incorporates a parameter for saturable protein binding, individual responses for blood pressure reduction and angiotensin converting enzyme inhibition were characterized in terms of the maximum effect (Emax) and the drug concentration required to produce 50% of Emax (Ce50). In individual subjects, plasma enalaprilat concentrations could be correlated with falls in blood pressure and changes in plasma angiotensin converting enzyme activity. For the group, Emax was -46.1 +/- 16.5 and -19.7 +/- 3.8 mm Hg for systolic and diastolic blood pressure, respectively, and the corresponding Ce50 values were 66.1 +/- 20.2 and 61.6 +/- 22.5 ng/ml. For angiotensin converting enzyme inhibition, Emax (%) and Ce50 (ng/ml) were, respectively, 102.4 +/- 5 and 19.8 +/- 13 after the first dose, 103 +/- 5 and 33.4 +/- 20.3 after 1 week, and 101.3 +/- 2.2 and 31.3 +/- 18.9 after 6 weeks. There was no relation between the responsiveness to enalapril (Emax or Ce50) and patient age or plasma renin activity, but there was a significant positive correlation between Emax and the pretreatment blood pressure. In individual subjects, Emax (first dose) was directly correlated with Emax after 1 and 6 weeks.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				J. M. LeBlanc, J. F. Dasta, M. C. Pruchnicki, and J. J. Schentag Impact of disease States on the pharmacokinetics and pharmacodynamics of Angiotensin-converting enzyme inhibitors. J. Clin. Pharmacol., September 1, 2006; 46(9): 968 - 980. [Abstract] [Full Text] [PDF]

				T.N. Dzeka, R. Townley, and J.M. O. Arnold Effects of enalaprilat on venoconstriction to norepinephrine: role of prostaglandins Cardiovasc Res, July 1, 2003; 59(1): 250 - 256. [Abstract] [Full Text] [PDF]

				D. V. Exner, D. L. Dries, M. J. Domanski, and J. N. Cohn Lesser Response to Angiotensin-Converting-Enzyme Inhibitor Therapy in Black as Compared with White Patients with Left Ventricular Dysfunction N. Engl. J. Med., May 3, 2001; 344(18): 1351 - 1357. [Abstract] [Full Text] [PDF]

				S. Ueda, P. A. Meredith, J. J. Morton, J. M. C. Connell, and H. L. Elliott ACE (I/D) Genotype as a Predictor of the Magnitude and Duration of the Response to an ACE Inhibitor Drug (Enalaprilat) in Humans Circulation, November 17, 1998; 98(20): 2148 - 2153. [Abstract] [Full Text] [PDF]

				J. A. Taylor, D. L. Carr, C. W. Myers, and D. L. Eckberg Mechanisms Underlying Very-Low-Frequency RR-Interval Oscillations in Humans Circulation, August 11, 1998; 98(6): 547 - 555. [Abstract] [Full Text] [PDF]